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Cyclosporine and its relative FK506are drugs used to treat autoimmunediseases and prevent rejection in
bone marrow and organ transplantation.
Originally identified by screening for antibi-
otics from microorganisms, these remark-
able drugs suppress the immune system by
altering activation of the genes that encode
immune factors. However, this suppression
must be balanced with the need to maintain
enough strength in the immune system to
combat infection. So, side effects of
cyclosporine treatment are not uncommon,
and include an increased risk of cancer in
patients who take these drugs long-term.
On page 530 of this issue, Hojo et al.1
describe how they have re-examined the pre-
sumed cause of cyclosporine-associated can-
cers. It was previously held that such cancers
result from a failure of the immune system
to eliminate cancerous cells — presumably
because, when treated with cyclosporine, the
immune system cannot detect and respond
to proteins associated specifically with the
tumours. But Hojo and colleagues suggest a
radically different explanation. They find
that cyclosporine itself alters the characteris-
tics of several cancerous cell lines in vitro and
in vivo. The authors believe that it does this
by inducing the synthesis of another molec-
ule known as transforming growth factor-b
(TGF-b).
Hojo et al. first found that, when exposed
to cyclosporine in vitro, cancerous cells
become more likely to divide, move and
spread — they change shape, show increased
mobility and, unlike normal cells, can grow
without being anchored to a solid surface.
Moreover, when the authors injected differ-
ent types of tumour cells into immune-defi-
cient mice, more secondary tumours devel-
oped in the lungs in the presence than in the
absence of cyclosporine. These results chal-
lenge assumptions about how cyclosporine-
associated tumours arise, and how immune
surveillance is involved in the development
of cancer. They also raise questions about
how cyclosporine suppresses immune func-
tion, suggesting a more general role than pre-
viously thought for cyclosporine-dependent
signalling pathways in human disease.
The mechanism of cyclosporine action
has been described by several laboratories
(reviewed in refs 2, 3). It was thought to block
the immune system by inhibiting signalling
through the T-cell receptor. The effect of this
is to prevent the production of cytokines that
would normally stimulate an immune
response (Fig. 1). But this explanation is not
necessarily complete. First, when one of
these cytokines, interleukin-2, is disrupted
in transgenic animals, the effect on immune
function is not the same as treatment with
cyclosporine4–7. Second, if another molecule
in the proposed signalling pathway (the
nuclear factor of activated T-cells, NF-AT) is
knocked out, again the effects do not match
treatment with cyclosporine8. 
An alternative explanation comes from
the fact that cyclosporine stimulates the pro-
duction of TGF-b9,10. We do not know how it
does this, but it is an important avenue of
further investigation because several previ-
ously mysterious side effects of cyclosporine
can be explained by the induction of TGF-b
(Fig. 2). For example, cyclosporine can cause
liver damage, and thickening and scarring of
the kidneys and skin — an effect also seen
with increased TGF-b11. Because TGF-b is
itself a well-known and potent immunosup-
pressive agent, increased production of TGF-
b — as wellas the inhibition of cytokine pro-
duction — could explain the activity of
cyclosporine. 
Hojo et al.1 have now recognized that, as
well as affecting immune function, TGF-b
might alter the behaviour of cancerous cells.
The remarkable changes that they observed
in cyclosporine-treated cancerous cell lines
were reversed when they added an antibody
that bound to (and therefore blocked the
action of) TGF-b. In the same way, the
increased spread of cancer cells in vivo was
also blocked by the TGF-b antibody. These
results indicate that treatment with
cyclosporine does not increase tumour
growth indirectly, by a failure of the immune
system, but rather directly through a non-
immune mechanism that acts on the tumour
itself via TGF-b receptors.
Hojo and colleagues’ study is certainly
provocative, calling into question the pro-
posed mechanism by which cyclosporine
induces secondary cancers. But several
caveats should be noted. For example, we do
not know whether cyclosporine has a similar
effect on precancerous cells, or whether it is
involved in converting cells from a benign to
a cancerous state. Nonetheless, the data do
indicate that cyclosporine and its relatives
could exacerbate tumour growth in patients
with existing tumours.





Many transplant patients are given the drug cyclosporine to suppress
their immune systems and prevent rejection. But cyclosporine also
increases the risk of cancer, always thought to be a side effect of the
depressed immune system. A new study shows that cyclosporine












Figure 1 Previously defined mechanism for the
action of cyclosporine. After binding to
cyclophilin, cyclosporine inhibits calcineurin,
which normally removes a phosphate group
from members of the nuclear factor of activated
T-cells (NF-AT) family. This dephosphorylation
normally promotes movement of NF-AT to the
nucleus, where it stimulates expression of the
genes for interleukin-2 and other stimulatory
cytokines. Inhibition by cyclosporine blocks
cytokine expression and prevents an immune
response.
Figure 2 Emerging ideas about the action of
cyclosporine. Hojo and colleagues1 have shown
that cyclosporine may cause cancer by stimulating
production of the transforming growth factor-b
(TGF-b), although it is not yet known how it does
this. TGF-b may then: a, stimulate the growth of
existing cancers; b, cause liver damage, and
thickening and scarring of the skin or kidneys; or
c, suppress immune responses. d, Cyclosporine
may also be used to treat heart disease by
inhibiting thickening of the heart muscle.
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Other studies point to a broader involve-
ment of the signalling pathway triggered by
cyclosporine in tissues outside the immune
system. Molkentin, Olson and colleagues12,
for example, have reported that increasing
the expression of activated NF-AT3 in the
heart muscle of transgenic mice leads to
enlargement of the cardiac tissue (cardiac
hypertrophy). Cardiac hypertrophy can be
inhibited by giving mice cyclosporine13,
although it is not clear whether TGF-b is
the mediator involved here. An alternative
explanation may come from the finding that
cyclosporine-mediated inhibition of calc-
ineurin blocks the expression of muscle-spe-
cific genes, preventing hypertrophy14. What-
ever the mechanism, these results indicate
that a cyclosporine-like agent could be used
to treat heart disease. However, such treat-
ment would probably not be given unless the
effects of cyclosporine on the immune sys-
tem could somehow be reduced.
Hojo and colleagues’ study will raise con-
cerns about the increased incidence of cancer
associated with cyclosporine treatment. This
complication is, however, a well-known side
effect of cyclosporine therapy, one that is
currently balanced against the need to treat
life-threatening diseases. The new observa-
tions do not alter this risk, nor do they sug-
used semi-inclusive deep-inelastic scattering
of a positron beam to identify the contribu-
tion of individual quarks to the momentum of
the proton. Both groups see an excess of virtu-
al down-antiquarks over up-antiquarks, con-
tradicting predictions that the two flavours of
antiquark should be present inside the proton
in equal numbers.
Elastic scattering is what happens with
billiard balls — they collide and bounce
without changing their identity and with no
significant loss of kinetic energy. Inelastic
scattering usually means that one or both of
the colliding objects has been changed by the
collision, in that they may be deformed or
broken into pieces like a billiard ball shat-
tered by a bullet. Deep-inelastic scattering is
a subtle amalgam of the two, as if a bullet
shatters a billiard ball but in the process
makes a quasi-elastic collision with a heavy,
compact ball-bearing buried inside the tar-
get. Particle physicists began to believe in the
reality of quarks in the early 1970s (ref. 3),
when deep-inelastic scattering experiments
with electrons (bullets) on protons (billiard
balls) gave far more large-angle electron
scatters than expected. The results can be
explained only if there are heavy, compact
objects (the quarks, equivalent to the buried
ball-bearings) inside the protons.
This raises an obvious question: if an
electron has a quasi-elastic scatter on a
quark, should we not see the quark recoiling
at a large angle too, leaving the shards of the
proton behind? The answer is “Yes, but it is
more complicated than that”. What obscures
the simple picture is a property of quarks
that makes them harder to study than most
other elementary particles, the fact that a
single free quark can never be seen on its
own. They are like the poles of a bar magnet
— cut it in two and you don’t get two free
poles, you get two smaller magnets each with
two poles. According to the successful theory
of quantum chromodynamics (QCD),
quarks are always surrounded by a local
cloud of force-carrying particles called glu-
ons, which act like the magnetic field around
a magnetic pole. If we scatter an electron vio-
lently from a quark in a proton, then the
quark begins to recoil like a free particle. But
when it gets more than about 1 femtometre
(10115 m) from the remains of the proton, it
stretches the gluon field sufficiently to allow
a new quark–antiquark pair to be produced,
and the antiquark sticks to the original quark
and makes a meson.
In highly energetic collisions, many
quark–antiquark pairs are created, producing
a jet (Fig. 1) of mesons (see ref. 4 for a qualita-
tive explanation, or ref. 5 for the full treat-
ment). But QCD theory says that the meson
with the largest momentum will contain the
original recoiling quark. A p& meson con-
tains an up-quark and a down-antiquark; a
p1 contains a down-quark and an up-anti-
quark, so by looking at the fastest meson we
can infer something about which kind of
quark (or antiquark) in the target proton was
hit. Experiments that pick out this leading
meson for special attention are making use of
semi-inclusive deep-inelastic scattering.
That is what the HERMES collaboration1
has done: they scattered 27.5 GeV positrons
(the same as electrons for these purposes)
from both protons and neutrons contained
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gest that any additional precautions be taken
beyond those already recognized. But they
do provide an insight into how these cancers
come about, and may be useful in treating
them. The results could also provide a lead
in the search for new immunosuppressive
drugs that might be more selective. But
cyclosporine, whose mechanism of action
was thought to be well understood, remains
enigmatic in many respects.
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Since the proton is the lightest stablecomposite object in the Universe wemight expect it to be the simplest. Yet its
structure is much more complicated than we
can explain with current theories, as reported
in Physical Review Lettersby the HERMES col-
laboration1 at the HERA accelerator in Ham-
burg and by the NuSea collaboration2 at the
Fermilab Tevatron near Chicago. HERMES
























Figure 1 Principle of the HERMES experiment1. a, Feynman graph for semi-inclusive deep-inelastic
positron scattering from a valence up-quark in a proton. The exchanged photon is the carrier of the
electromagnetic force. If the leading meson is charged, it has to be a p& because the recoiling quark is
an up-quark. Arrows pointing backwards in time represent antiparticles. b, Semi-inclusive deep-
inelastic scattering from a virtual up-antiquark (uá) in the sea, formed by pair production from a
virtual gluon. The leading charged meson in this case has to be a p1, whereas if the scattering were
from a down-antiquark it would be a p&.
